Rule 497(d)
FT 422
Biotechnology Select Portfolio, Series 3
Digital Convergence Select Portfolio, Series 2
Fiber Optics Select Portfolio, Series 2
Genomics & Proteomics Select Portfolio, Series 2
Pharmaceutical Select Portfolio, Series 3
Storage & Networking Select Portfolio Series
Technology Select Portfolio, Series 3
Biotechnology Portfolio, Series 3
Digital Convergence Portfolio, Series 2
Fiber Optics Portfolio, Series 2
Genomics & Proteomics Portfolio, Series 2
Pharmaceutical Portfolio, Series 9
Storage & Networking Portfolio Series
Technology Portfolio, Series 12
Supplement to the Prospectus dated March 22, 2000
Notwithstanding anything to the contrary in the Prospectus, Unit holders who
acquire Units of Genomics & Proteomics Select Portfolio, Series 2, Genomics &
Proteomics Portfolio, Series 2 or Storage & Networking Portfolio Series which,
as a result of a reduction in the aggregate underlying value of the Securities,
are not subject to an initial sales charge will be subject to the maximum
remaining deferred sales charge (initially $.225 per Unit in the case of
Genomics & Proteomics Select Portfolio, Series 2 or $.35 per Unit for Genomics
& Proteomics Portfolio, Series 2 or Storage & Networking Portfolio Series). In
such case the maximum sales charge may exceed 3.25% of the Public Offering Price
per Unit for Genomics & Proteomics Select Portfolio, Series 2 or 4.5% of the
Public Offering Price per Unit for Genomics & Proteomics Portfolio, Series 2 or
Storage & Networking Portfolio Series, but in no event will the maximum sales
charge exceed 3.75% of the Public Offering Price per Unit for Genomics
& Proteomics Select Portfolio, Series 2, 5.00% of the Public Offering Price per
Unit for Storage & Networking Portfolio Series or 5.50% of the Public Offering
Price per Unit for Genomics & Proteomics Portfolio, Series 2.
April 4, 2000
